

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

NCT07169851

Status	RECRUITING
Phase	Phase 2
Sponsor	Eli Lilly and Company
Enrollment	204 participants

Key Eligibility Criteria

Inclusion (2)

- Chemotherapy-naive participants, planned to receive AC or cisplatin-based chemotherapy greater than or equal to (e)70 milligrams per square meter (mg/m²), on Day 1 of each cycle, with no multiple administrations during the CINV observation period, from Day 2 to Day 5 of each cycle.
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

Exclusion (8)

- Have symptomatic or untreated central nervous system (CNS) metastases.
- Have an established diagnosis of uncontrolled diabetes mellitus.
- Have a history of, or current evidence of, a clinically significant cardiac condition or QT/QTcF-related conditions.
- Have another etiology for nausea and vomiting, or receives medications with know or potential antiemetic activity
- Signs, symptoms or history of thyroid tumors

... and 3 more (see full listing online)

Locations (67 total)

Marin Cancer Care, Greenbrae, California, United States
City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States
Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
... and 64 more locations